Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AGIO NASDAQ:ITOS NASDAQ:MESO NASDAQ:STOK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGIOAgios Pharmaceuticals$31.84+0.1%$29.21$22.24▼$46.00$1.89B0.59931,925 shs788,088 shsITOSiTeos Therapeutics$10.15$10.14$6.18▼$11.35$448.73M1.311.57 million shsN/AMESOMesoblast$13.75-0.1%$14.90$9.88▼$21.50$1.78B2.05156,776 shs124,880 shsSTOKStoke Therapeutics$29.15-2.8%$32.19$11.17▼$40.22$1.87B1.17520,882 shs410,747 shsDon't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGIOAgios Pharmaceuticals+8.01%+15.96%+12.96%+10.07%-7.23%ITOSiTeos Therapeutics0.00%0.00%0.00%0.00%-0.20%MESOMesoblast-1.22%-0.29%-8.21%-5.30%+16.81%STOKStoke Therapeutics+0.60%+3.45%-0.27%-8.73%+160.19%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGIOAgios Pharmaceuticals$31.84+0.1%$29.21$22.24▼$46.00$1.89B0.59931,925 shs788,088 shsITOSiTeos Therapeutics$10.15$10.14$6.18▼$11.35$448.73M1.311.57 million shsN/AMESOMesoblast$13.75-0.1%$14.90$9.88▼$21.50$1.78B2.05156,776 shs124,880 shsSTOKStoke Therapeutics$29.15-2.8%$32.19$11.17▼$40.22$1.87B1.17520,882 shs410,747 shsDon't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGIOAgios Pharmaceuticals+8.01%+15.96%+12.96%+10.07%-7.23%ITOSiTeos Therapeutics0.00%0.00%0.00%0.00%-0.20%MESOMesoblast-1.22%-0.29%-8.21%-5.30%+16.81%STOKStoke Therapeutics+0.60%+3.45%-0.27%-8.73%+160.19%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAGIOAgios Pharmaceuticals 2.45Hold$40.8928.42% UpsideITOSiTeos Therapeutics 2.33Hold$10.755.91% UpsideMESOMesoblast 2.33HoldN/AN/ASTOKStoke Therapeutics 2.73Moderate Buy$41.8343.51% UpsideCurrent Analyst Ratings BreakdownLatest ITOS, MESO, STOK, and AGIO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/11/2026AGIOAgios Pharmaceuticals JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$36.00 ➝ $31.005/29/2026AGIOAgios Pharmaceuticals Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$41.00 ➝ $40.005/11/2026STOKStoke Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C) ➝ Sell (D)5/11/2026STOKStoke Therapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$39.004/30/2026AGIOAgios Pharmaceuticals Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$39.00 ➝ $36.004/21/2026MESOMesoblast Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/21/2026AGIOAgios Pharmaceuticals Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$44.00 ➝ $41.004/20/2026AGIOAgios Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$65.00 ➝ $50.004/10/2026STOKStoke Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)4/6/2026AGIOAgios Pharmaceuticals JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$31.00 ➝ $36.004/1/2026AGIOAgios Pharmaceuticals The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$28.00 ➝ $32.00(Data available from 6/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAGIOAgios Pharmaceuticals$54.03M35.05N/AN/A$20.46 per share1.56ITOSiTeos Therapeutics$35M12.82N/AN/A$11.17 per share0.91MESOMesoblast$17.20M103.49N/AN/A$4.67 per share2.94STOKStoke Therapeutics$184.42M9.84N/AN/A$6.17 per share4.72Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAGIOAgios Pharmaceuticals-$412.78M-$7.25N/AN/AN/A-639.84%-34.11%-31.66%7/30/2026 (Estimated)ITOSiTeos Therapeutics-$134.41M-$4.67N/AN/AN/AN/A-33.26%-28.16%N/AMESOMesoblast-$102.14M-$0.54N/AN/AN/AN/AN/AN/A9/2/2026 (Estimated)STOKStoke Therapeutics-$6.89M-$2.81N/AN/AN/A-529.20%-48.84%-42.27%8/11/2026 (Estimated)Latest ITOS, MESO, STOK, and AGIO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026STOKStoke Therapeutics-$0.80-$0.79+$0.01-$0.79$6.48 million$6.23 million4/29/2026Q1 2026AGIOAgios Pharmaceuticals-$1.81-$1.69+$0.12-$1.69$13.30 million$20.75 million3/16/2026Q4 2025STOKStoke TherapeuticsN/A-$0.97N/A-$0.97N/A$1.40 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAGIOAgios PharmaceuticalsN/AN/AN/AN/AN/AITOSiTeos TherapeuticsN/AN/AN/AN/AN/AMESOMesoblastN/AN/AN/AN/AN/ASTOKStoke TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAGIOAgios PharmaceuticalsN/A14.1913.59ITOSiTeos TherapeuticsN/A7.537.53MESOMesoblast0.101.581.41STOKStoke TherapeuticsN/A8.998.99Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAGIOAgios PharmaceuticalsN/AITOSiTeos Therapeutics97.16%MESOMesoblast1.43%STOKStoke TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipAGIOAgios Pharmaceuticals5.40%ITOSiTeos Therapeutics14.20%MESOMesoblast18.80%STOKStoke Therapeutics9.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAGIOAgios Pharmaceuticals39059.47 million56.26 millionOptionableITOSiTeos Therapeutics9044.21 million37.93 millionOptionableMESOMesoblast80129.46 million105.12 millionOptionableSTOKStoke Therapeutics10062.28 million56.37 millionOptionableITOS, MESO, STOK, and AGIO HeadlinesRecent News About These CompaniesStoke Therapeutics, Inc. (NASDAQ:STOK) Receives Average Recommendation of "Moderate Buy" from AnalystsJune 15 at 2:32 AM | americanbankingnews.comStoke Therapeutics, Inc. (NASDAQ:STOK) Receives Average Rating of "Moderate Buy" from AnalystsJune 15 at 2:31 AM | marketbeat.comRhenman & Partners Asset Management AB Lowers Position in Stoke Therapeutics, Inc. $STOKJune 13 at 5:48 AM | marketbeat.comStoke Therapeutics (NASDAQ:STOK) Trading Up 1.6% - Should You Buy?June 12, 2026 | marketbeat.comStoke Therapeutics, Inc. (STOK) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptJune 8, 2026 | seekingalpha.com4 Biotech Stocks Investors Should Watch in 2026June 5, 2026 | zacks.comStoke Therapeutics Stockholders Approve Directors and Governance ItemsJune 4, 2026 | tipranks.comStoke Therapeutics (STOK) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?June 4, 2026 | zacks.comBarry Ticho Sells 1,795 Shares of Stoke Therapeutics (NASDAQ:STOK) StockJune 4, 2026 | insidertrades.comStoke Therapeutics, Inc. (STOK) Reports Q1 Results and Business UpdatesJune 1, 2026 | insidermonkey.comStoke Therapeutics to Present at Upcoming Investor Conferences in JuneMay 29, 2026 | finance.yahoo.comUBS Group AG Decreases Stock Position in Stoke Therapeutics, Inc. $STOKMay 22, 2026 | marketbeat.comIs it a Good Idea to Invest in Stoke Therapeutics Stock Now?May 21, 2026 | zacks.comStoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)May 18, 2026 | businesswire.comStoke Therapeutics, Inc. (NASDAQ:STOK) Analysts Are Pretty Bullish On The Stock After Recent ResultsMay 12, 2026 | finance.yahoo.comStoke Therapeutics, Inc. 2026 Q1 - Results - Earnings Call PresentationMay 11, 2026 | seekingalpha.comAnalysts Offer Insights on Healthcare Companies: Definium Therapeutics (DFTX), Guardant Health (GH) and Stoke Therapeutics (STOK)May 10, 2026 | theglobeandmail.comStoke outlines Q1 2027 rolling NDA start as EMPEROR enrollment targets June, backed by $411M cash balanceMay 8, 2026 | seekingalpha.comStoke Therapeutics Announces First Quarter 2026 Financial Results and Provides Business UpdatesMay 8, 2026 | finance.yahoo.comStoke Therapeutics, Inc. (STOK) Q1 2026 Earnings Call TranscriptMay 8, 2026 | seekingalpha.comStoke Therapeutics, Inc. (STOK) Reports Q1 Loss, Tops Revenue EstimatesMay 7, 2026 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeITOS, MESO, STOK, and AGIO Company DescriptionsAgios Pharmaceuticals NASDAQ:AGIO$31.84 +0.02 (+0.06%) Closing price 04:00 PM EasternExtended Trading$31.42 -0.41 (-1.30%) As of 05:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.iTeos Therapeutics NASDAQ:ITOSiTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.Mesoblast NASDAQ:MESO$13.75 -0.01 (-0.07%) Closing price 04:00 PM EasternExtended Trading$13.72 -0.03 (-0.22%) As of 07:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.Stoke Therapeutics NASDAQ:STOK$29.15 -0.85 (-2.83%) Closing price 04:00 PM EasternExtended Trading$28.63 -0.52 (-1.78%) As of 05:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Gravity Check: Houston, SpaceX Has a Valuation Problem Okta’s AI Moment May Be Bigger Than Investors Realize Strategy’s Bitcoin Rally Has a Hidden Engine Is Lennar Finally Turning the Corner After Its Housing Slump? Plot Twist: How the $110B Paramount-Warner Deal Rewrites Media AST SpaceMobile Announces Launch Date for Its Next 3 BlueBird Satellites Insiders Sell Top Tech Plays: Should Investors Buy, Sell, or Hold? What's Behind the Social Media Controversy Surrounding IonQ? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
